3 US Penny Stocks With Market Caps Over $40M To Consider

In This Article:

U.S. stocks have shown resilience as the Nasdaq Composite leads a market rally, with investors brushing off tariff threats and focusing on growth opportunities. For those looking beyond major indices, penny stocks—typically representing smaller or newer companies—continue to offer intriguing prospects despite their historical connotations. While the term might seem outdated, the potential for growth remains significant, especially when these companies boast strong financials and clear growth paths.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.88875

$6.46M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$125.23M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.94

$89.18M

★★★★★★

North European Oil Royalty Trust (NYSE:NRT)

$4.71

$43.29M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.42

$46.86M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.69

$46.67M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.41

$25.01M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8834

$79.45M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.60

$384.4M

★★★★☆☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Dyadic International

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Dyadic International, Inc. is a biotechnology platform company that develops, produces, and sells enzymes and other proteins both in the United States and internationally, with a market cap of $48.53 million.

Operations: The company's revenue segment is derived entirely from its biotechnology business, generating $3.36 million.

Market Cap: $48.53M

Dyadic International, Inc. is a biotechnology company with a market cap of US$48.53 million and revenue of US$3.36 million, indicating it does not have meaningful revenue yet. Despite being unprofitable, the company has reduced its losses over the past five years by 3.7% annually and maintains more cash than debt, offering some financial stability with short-term assets exceeding liabilities. However, its negative return on equity and increasing weekly volatility highlight ongoing challenges in achieving profitability or stable growth in the near term. Recent conference presentations suggest active engagement within the biotech community to potentially bolster future prospects.

NasdaqCM:DYAI Financial Position Analysis as at Feb 2025
NasdaqCM:DYAI Financial Position Analysis as at Feb 2025

Newegg Commerce

Simply Wall St Financial Health Rating: ★★★★★★